Introduction
CD22 is a B lineage-restricted member of the Ig superfamily (1,2) that functions as both an adhesion and signaling receptor. It is a sialic acid-binding lectin, with specificity for glycoconjugates containing terminal α-2,6-linked sialic acids (3) (4) (5) (6) (7) . Binding of CD22 to its ligands can be modulated not only by the α-2,6-sialyltransferase which creates the CD22 ligand (8) , but also by enzymes that regulate the acetylation state of the polyhydroxylated side chain of sialic acids (9) . Ligands for CD22 have been identified on the cell surface of erythrocytes, monocytes, activated endothelial cells, T cells and B cells (6, (10) (11) (12) (13) (14) . Immunoprecipitation studies using recombinant murine CD22 identified CD22 itself as well as the B lineage isoform of CD45, B220, as two of several CD22 ligands expressed on B cells (6) . These studies further demonstrated that early IgM -B cell progenitors in the bone marrow express ligands for CD22 (6) .
CD22 also acts as an accessory molecule for B cell receptor (BCR) signaling. Upon engagement of the BCR or direct engagement of CD22 using mAb, CD22 is rapidly phosphoryl- ated on cytoplasmic tyrosine residues allowing signaling molecules to interact with CD22 through SH2 interactions (15) (16) (17) . Phosphatidyl inositol-3 kinase, p53/56 lyn , p72 syk and SHP1 have all been found to associate with CD22 following stimulation (18) (19) (20) (21) (22) . Ligation of CD22 to prevent its coaggregation with surface Ig (sIg) has been shown to lower the threshold at which sIg activates B cells (21, 23, 24) . Since SHP1 is known to negatively regulate antigen receptor signaling in B cells (25, 26) , sequestration of CD22-associated SHP1 away from the BCR complexes is thought to lower signaling thresholds. Consistent with this, splenic B cells from CD22-deficient mice exhibited an augmented intracellular calcium response after cross-linking of sIg (27) (28) (29) . More recently, engagement of CD22 with mAb has been shown to augment signals delivered not only via the BCR, but also the CD40, IL-2 and IL-4 receptors (30) . These results suggest that the CD22 signal transduction pathway may be functionally important at several distinct phases of B cell differentiation. Studies of human CD22 demonstrated that it is expressed in the cytoplasm of pre-B cells and on the cell surface of mature B cells, after acquisition of IgM (31 
Methods

Mice
C57BL/6 mice, 6-8 weeks old, were purchased from Jackson Laboratories (Bar Harbor, ME). µMT mice were generated in the laboratory of Dr Klaus Rajewsky (33) and provided by Dr Len Shultz (Jackson Laboratories). Mice were housed at the animal facility at the Wellesley Hospital Research Institute. Timed pregnancies were scheduled as previously described (34) .
Cell purification
Cell suspensions from fetal liver and bone marrow were prepared by passage through a 26-gauge needle. Cell suspensions of splenic cells were prepared by mincing over a metal screen with a syringe plunger. Debris was removed by gravity sedimentation for 5 min on ice. Erythrocytes from bone marrow and splenic cells were lysed with ACK (0.155 M ammonium chloride, 0.1 mM disodium EDTA, 0.01 M potassium bicarbonate, pH 7.3) for 5 min on ice. Cell viability was determined by Trypan blue exclusion. B cell progenitor enrichment of day 15 fetal liver cells was performed as described using Optilux 100 mm plastic Petri dishes (Falcon no. 1001; Becton Dickinson, Mountain View, CA) (35) . Petri dishes were coated with mouse anti-rat IgG (5 µg/ml; Jackson Immunoresearch, Jackson, ME) in 0.05 M Tris-HCl, pH 9.5, 0.15 M NaCl at room temperature for a minimum of 1 h. After washing the plates 3 times in 5% FCS/BSS, 5 ml anti-B220 hybridoma supernatant (mAb 14.8) (35), diluted 1:2, was applied overnight at 4°C. The dishes were washed 3 times in 5% FCS/BSS and cell suspensions were then added for 60 min at 4°C. Adherent B220 ϩ cells were recovered by scraping with a plastic scraper (no. 3010; Costar, Cambridge, MA) after carefully washing the plates 8 times in 5% FCS/BSS.
Cell culture conditions
Cells were maintained in OPTI-MEM (Gibco/BRL, Grand Island, NY) supplemented with 10% FCS, 50 µM 2-mercaptoethanol, 2.4 g/l NaHCO 3 , 100 U/ml penicillin, 100 µg/ml streptomycin (Gibco/BRL) and the indicated factors. IL-7 (Immunex, Seattle, WA) was used at 100 U/ml. 
Limiting dilution analysis
To determine IL-7 frequencies, sorted bone marrow cells were cultured in limiting dilutions (32 replicates/cell concentration) in a 96-well plate with IL-7 for 5 days. B220 ϩ µ -CD22 -and B220 ϩ µ -CD22 lo cell populations were cultured at 3, 6, 12, 25, 50 and 100 cells/well. B220 ϩ µ ϩ CD22 hi cells were cultured at 12, 25, 50, 100, 200 and 400 cells/well. On day 5 wells were scored for positive colonies containing Ͼ40 cells. To determine S17 ϩ LPS frequencies, sorted bone marrow cells were plated at limiting dilutions (32 replicates/cell concentration) in a 96-well plate containing 1000 irradiated S17 stromal cells/well and 15 µg/ml LPS (Salmonella typhosa W0901; Difco, Detroit, MI). B220 ϩ µ -CD22 -cells were cultured at 6, 12, 25, 50, 100 and 200 cells/well, B220 ϩ µ -CD22 lo at 1, 3, 6, 12, 25 and 50 cells/well, and B220 ϩ µ ϩ CD22 hi. at 0.5, 1, 3, 6, 12 and 25 cells/well. Cultures were maintained for 14 days and the concentration of IgM in the culture supernatant was determined by ELISA. The fraction of wells which were negative for IgM production was plotted against the number of initial cells per well using least-squares regression. The frequency of responsive B cell progenitors was determined as the number of initial cells per well where 37% of the wells were non-responding (i.e. negative for IgM production).
ELISA
EIA plates (no. 3590; Costar) were coated with 5 µg/ml affinity-purified goat anti-mouse µ chain antibody (Jackson Immunoresearch) for 60 min at room temperature. Plates were blocked for 30 min with 5% FCS/PBS followed by eight washes with cold tap water. Then 50 µl of culture supernatants were added to the plates, incubated at 37°C for 30 min and washed 8 times in cold tap water. A 1:2000 dilution of goat anti-mouse µ chain conjugated to horseradish peroxidase (Sigma, St
Louis, MO) was added for 30 min at 37°C. After washing 8 times, 50 µl of substrate consisting of 0.5 mg/ml 2,2Ј-azinobis(3-ethylbenzthiazoline-6-sulfonic acid), 0.05 M phosphate citrate buffer and 0.03% sodium perborate (Sigma) was added. The plates were incubated for 30 min at 37°C and the absorbence was read at 405/630 nm.
Isolation of resting B cells and B cell activation
Small resting B cells were obtained following the procedure of Julius et al. (36) . Briefly, erythrocyte-free spleen cells were treated with anti-Thy-1.2 (HO 13.4.9), anti-CD4 (RL 172.4H) and anti-CD8 (3.168) antibody supernatants (1:20 dilution) followed by the addition of guinea pig complement (1:12 dilution) (Cedarlane, Hornby, Ontario, Canada) for 1 h at 37°C. The T-depleted spleen cells were added to a Percoll gradient (5-10ϫ10 6 cells/5 ml gradient) as described. 
Results
CD22 is expressed on the cell surface prior to the expression of IgM
The pattern of CD22 expression on murine bone marrow cells was determined by three-color immunofluorescence analysis using mAb recognizing B220, µ heavy chain and CD22 (Fig. 1A) . We found that the mature B cells (B220 bright µ ϩ ) express high levels of CD22, whereas the B cell progenitors (B220 ϩ µ -) express low levels of CD22 (Fig. 1B) . These results clearly demonstrate that CD22 is expressed prior to the expression of IgM, albeit at lower levels. Immature bone marrow B cells (B220 dull µ ϩ ) express intermediate levels of CD22. B220 ϩ bone marrow cells were divided further into pro-B cells, which express CD43, and pre-B, immature and mature B lineage cells, which do not (37) . This analysis revealed that, while 4% of the B220 ϩ cells express CD43 and CD22 (Ͻ1% were stained using isotype-matched antibodies), the majority of B220 ϩ CD43 ϩ pro-B cells fail to express CD22 (Fig. 1C) . These data suggest that early B lineage cells begin to express CD22 as they lose expression of CD43. We next analyzed bone marrow cells from mice homozygous for a mutation in the membrane exon of the Ig µ chain gene (µMT) (33) (Fig. 1D) . B cell development in µMT mice is blocked at the CD43 ϩ to CD43 -transition. Consequently there is an accumulation of B220 ϩ CD43 ϩ pro-B cells in the bone marrow.
Although the majority of the pro-B cells are CD22 -, 17% of these cells express CD22 (Ͻ1% were stained with an isotype matched antibody) (Fig. 1D ). Together these analyses define three populations of B cell progenitors; B220 ϩ CD43 ϩ CD22 -early pro-B cells, B220 ϩ CD43 ϩ CD22 lo late pro-B cells and B220 ϩ CD43 -CD22 lo pre-B cells. The expression of CD22 on IgM ϩ bone marrow cells was further analyzed (Fig. 2A) . We found that bone marrow cells which express high levels of both µ heavy chain and κ light chain express high levels of CD22, whereas cells which express lower levels of µ and κ express low levels of CD22. These analyses suggest that the highest levels of CD22 expression are found on mature recirculating B cells. We next examined CD22 expression on splenic B cells (Fig. 2B) . As reported previously by others, all B220 ϩ splenic B cells continue to express high levels of CD22 (28) . B cell subsets in the spleen have been defined using the cell surface markers IgM and IgD (38) . Splenic B cells with low densities of IgM and high densities of IgD are at a more mature stage of development than those with high IgM and low IgD. According to these criteria, the less mature IgM hi IgD lo cells express slightly lower levels of CD22 than the IgM lo IgD hi B cells.
CD22 expression increases as B cell progenitors from the fetal liver mature in vitro
The analysis described thus far suggests that CD22 expression increases as B cells mature. To further define the onset and increase of CD22 expression, we utilized an in vitro assay which allows us to study the progression of committed, fetal liver-derived B cell progenitors to the stage of mature B lymphocytes (39) . This culture system defines two distinct stages of B cell development. The first stage is an IL-7-dependent proliferative phase in which a limited expansion of B cell progenitors occurs. The response to IL-7 allows cells to mature to a second stage where they can interact with the stromal cell line, S17, and mature to an IgM-secreting B cell in the presence of the polyclonal activator, LPS. B cell progenitors, enriched by panning B220 ϩ cells from day 15 fetal liver, were expanded in IL-7 for 4 days and then transferred to culture conditions containing either IL-7 or S17 and LPS. Cells were then harvested at 24, 48 and 72 h, and double stained for the expression of CD22 and BP-1 (Fig. 3A) . High expression of the cell surface marker BP-1 (aminopeptidase A) correlates with IL-7-responsive B cell progenitors (37, 40, 41) . As B cell progenitors mature, BP-1 expression declines (37) . Cells expanded in IL-7 maintain high expression of BP-1 and express low levels of CD22 (Fig. 3A) . This result further confirms that CD22 expression precedes µ surface expression, since the majority of the IL-7-responsive B cell progenitors are µ - (Fig. 3B) . Furthermore, of the cells which express low levels of CD22, 59-63% are cytoplasmic µ -. Cells which mature to mitogen responsiveness in the presence of both S17 and LPS begin to lose expression of BP-1 after 24 h of culture. A gradual increase in the surface density of CD22 molecules is seen as IL-7-expanded cells are kept in culture with S17 and LPS for 72 h. The observed increase in CD22 expression correlates with an increase in µ surface expression (Fig. 3B) and decrease in BP-1 expression (Fig. 3A) , validating the use of CD22 as a maturation marker in B cell development.
CD22 expression correlates with functional stages of B cell maturation
The growth factor IL-7 supports the proliferation of early committed B cell precursors (39) . As cells progress along the B lineage pathway, they lose responsiveness to IL-7. Studies in our laboratory have further shown that cells require an IL-7 response to mature to a stage where they can interact with stroma and become mitogen responsive (42) . The differential response of B lineage cells to these culture conditions can be used to characterize the stage of differentiation. To assess if loss of IL-7 responsiveness correlates with increasing CD22 expression, we fractionated bone marrow cells into three populations: B220 ϩ µ -CD22 -, B220 ϩ µ -CD22 lo and B220 ϩ µ ϩ CD22 hi (Fig. 4A) . The frequency of cells responding to IL-7 in the sorted populations was then determined by limiting dilution analysis (Fig. 4B) . The frequency of the B220 ϩ µ -CD22 -cell population was consistently Ͼ2-fold than that of the B220 ϩ µ -CD22 lo population. Cells which express the µ heavy chain and high levels of CD22 did not respond to IL-7, indicating that they are more mature and past the stage of IL-7 responsiveness. To measure the frequency of cells which mature beyond the stage of IL-7 responsiveness and are able to respond to mitogen in the presence of stromal cells, sorted cells were directly cultured in limiting dilutions with S17 and LPS (Fig. 4B) . As the frequency of response to IL-7 decreases in the three populations, there is a corresponding increase in the frequency with which cells become mitogen responsive. These functional data are consistent with the interpretation that as B cells mature, the levels of CD22 expressed on the cell surface increases.
Comparison of the role of CD22 in BCR-versus LPS-mediated activation
Since CD22 has been shown to play a role in cell signaling, we monitored expression of CD22 following activation of B cells. Resting splenic B cells from C57BL/6 mice were activated in vitro with either LPS or anti-µ antibodies and cells were stained for CD22 expression at days 0-4 (Fig. 5) . After LPS activation, levels of CD22 expression declined. By day 4,~70% of stimulated cells expressed surface CD22 at low density, whereas the remaining cells maintained a high level of CD22 expression (Fig. 5A) . Following anti-µ stimulation, a more rapid decrease in CD22 expression was observed; levels of CD22 expression decreased starting at day 2 (Fig. 5B) . In contrast to LPS stimulation, there was a shift of the entire population towards low CD22 expression. These results show that CD22 expression is modulated following activation. Furthermore, expression of CD22 appears to be differentially regulated in response to two distinct activation signals.
We next compared the role of CD22 in BCR-versus LPSmediated signaling pathways. Anti-µ mAb alone or with anti-CD22 mAb or isotype-matched mAb was added to small resting splenic B cells and proliferation was measured by thymidine incorporation (Fig. 6A) . In cultures stimulated with 10 µg/ml anti-µ mAb in the presence of 10 µg/ml anti-CD22 mAb, a 2-fold increase in thymidine incorporation over the level induced by anti-µ mAb alone was observed (P Ͻ 0.01 by two-tailed Student's t-test). Enhanced proliferative responses were not observed using isotype-matched mAb controls. Interestingly, engagement of the CD22 receptor also enhanced proliferation of LPS-stimulated B cells (Fig. 6B) . Proliferation of cells stimulated with LPS and 10 µg/ml anti-CD22 mAb was statistically greater than proliferation in response to LPS alone (P Ͻ 0.01 by two-tailed Student's t-test).
Discussion
Over the past few years, an increasing number of reports have demonstrated that the B lineage-restricted glycoprotein, CD22, is an important molecule involved in mediating adhesion events and in regulating thresholds for signaling through the BCR. Although expression of CD22 has been characterized by others (32, 43) , our results demonstrate that CD22 is expressed on the cell surface at an earlier time point during B cell development than previously reported. We show that CD22 is expressed at a low density on early B lineage cells (B220 ϩ IgM -) from the bone marrow and IL-7 expanded IgM -B cell progenitors from day 15 fetal liver. In the bone marrow, the majority of B lineage cells expressing low levels of CD22 fall into a subset of B cell precursors termed fraction D by Hardy et al. (37) . A small subset of B220 ϩ cells, however, expresses CD43 and CD22, suggesting that expression of CD22 can be found beginning in fraction C. Consistent with this, BP-1 ϩ cµ -fetal liver-derived B cell progenitors also express CD22. We further demonstrate that expression of CD22 increases during development. In the bone marrow, IgM ϩ B cells express higher levels of CD22 than IgM -B cell progenitors. The increasing expression of CD22 is also observed when B cell progenitors from day 15 fetal liver are allowed to mature in an in vitro culture system.
Previous studies examining the expression of CD22 failed to detect CD22 on IgM -B cell progenitors. One report using human bone marrow cells suggested that CD22 is expressed in the cytoplasm of pro-and pre-B cells, but that its expression on the cell surface correlated with IgM surface expression (31) . A more recent report on the expression of murine CD22 suggested that CD22 is first present at low levels on immature IgM hi B cells (32) . There may be several explanations for these discrepant results. To observe expression of CD22 on IgM -B cell progenitors, a clear discrimination of cells expressing low and high levels of CD22 must be achieved.
We have found that PE-rather than FITC-conjugated anti-CD22 mAb are more effective for this purpose. In the report by Erickson et al. on the expression of murine CD22 (32), the mean fluorescence intensity of CD22 on B220 ϩ IgM ϩ B cells was one order of magnitude greater than the isotype control, whereas it was consistently two orders of magnitude greater in our hands. This suggests that the separation of signal achieved previously was insufficient to discriminate between cells expressing low and high levels of CD22. A second reason may be attributed to the purity of the antibody preparation.
Erickson and colleagues utilized a reagent purified by ammonium sulfate precipitation (32) , whereas our studies relied on mAb purified by affinity chromatography. High levels of CD22 expression were observed on recirculating B220 bright IgM ϩ bone marrow cells, on resting splenic B cells, and on B cells derived from IL-7-expanded pro-B cells cultured with S17 and LPS for 72 h. These data are consistent with the interpretation that B cells poised to respond Comparison of the proliferative response of 10 µg/ml anti-CD22 ϩ 10 µg/ml LPS or ϩ 10 µg/ml anti-µ differed significantly from the response to 10 µg/ml Igγ1 ϩ 10 µg/ml LPS or ϩ 10 µg/ml anti-µ (P Ͻ 0.01 by two-tailed Student's t-test).
to antigen or mitogen express high levels of CD22. Resting splenic B cells isolated ex vivo can immediately respond to LPS, whereas IL-7 expanded fetal liver pro-B cells need 2-3 days before they mature to a stage when they can respond to LPS (manuscript submitted for publication). The high level of CD22 expression on fetal liver cells cultured in vitro may therefore be a result of their maturation on S17 and LPS and not a direct consequence of their response to LPS.
We have found that after B cell activation CD22 levels decline, however, the subsequent regulation of CD22 appears to depend upon the nature of B cell activation. After 4 days of LPS stimulation, the majority of cells expressed low levels of CD22 (Fig. 5A) . B cells which differentiate into plasma cells may express lower levels of CD22, whereas cells which retain high levels of CD22 may not have responded to LPS. In contrast to LPS stimulation, we observed a more rapid and uniform decrease in CD22 expression following anti-µ activation (Fig. 5B) . The observation that a decrease in CD22 expression was first observed at day 2 suggests that the decrease in expression was not an immediate consequence of IgM engagement or internalization. Studies using human B cells demonstrated that CD22 is lost from the cell surface after activation with anti-Ig or Protein A (31). Another report found that murine B cells activated with LPS ϩ IL-4 or CD40 ligand ϩ IL-4 retain high levels of CD22 (32) . Together these data suggest that, following activation of B cells, CD22 expression may be differentially regulated depending on the source of stimuli provided.
Previous studies have shown that ligating human CD22 prior to ligation of IgM increases BCR-mediated proliferation (21, 23, 24) . Recently, the addition of mAb against human CD22 has been shown to augment signals delivered not only via the BCR, but also CD40, IL-2R and IL-4R (30) . We show here that engagement of the murine CD22 receptor by mAb augments the proliferative signal delivered via LPS as well (Fig. 6B) . This result suggests that CD22 may be involved in thymus-independent responses. Consistent with this suggestion, studies of CD22-deficient mice reveal that CD22 is, in fact, required for normal antibody responses to thymusindependent antigens (28) . Whether the effects of sequestration of CD22 in this signaling pathway involve the same associated molecules as those implicated in the BCR-mediated activation pathway, such as the tyrosine phosphatase SHP1 (44), remains to be determined.
The expression of CD22 on B cell progenitors increases the likelihood that CD22 plays a role during B cell development. CD22 may, for example, mediate the contact between B cell progenitors and stromal cells that results in the maturation of these progenitors to a mitogen-responsive stage. It is also possible that CD22 mediates homotypic aggregation of B cell progenitors. A report using recombinant murine CD22 has shown that B220 ϩ IgM -B lineage cells in the bone marrow express ligands for CD22 (6) . An additional or alternative role for CD22 may be to provide signals independent of the BCR complex. A recent study suggests that cross-linking by certain anti-human CD22 mAb alone results in cell proliferation (30) . This raises the possibility that engagement of CD22 itself during development delivers a signal to the maturing cell.
Despite the early appearance of CD22 during B cell development, the numbers of B cell precursors appear normal in the bone marrow of CD22-deficient mice (27) (28) (29) . Such studies do not, however, indicate whether mechanisms which regulate positive and negative selection of progenitors are intact. In fact, the phenotype of CD22-deficient mice confirms that CD22 plays a significant role in BCR-mediated signaling in vivo. Analogous to its role on mature B cells, CD22 may control signaling thresholds on developing B cells, and therefore play an essential part in selection and tolerance induction. Our studies indicate that a closer examination of CD22-mediated activation pathways during B cell development is required.
